This dual role of TLR7 necessitates a stage-dependent, multi-target therapeutic strategy: using a TLR7 antagonist to mitigate inflammation during peak infection, and later employing strategies to counteract Th2 responses such as the TLR7 agonist or anti-IL5 mAb to prevent chronic airway hyperreactivity. Here, TLR7 is linked to infection.